Skip to main content

Table 2 Comparison of the clinical characteristics of good responders and poor responderss

From: Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer

 Total
(N = 102)
Good responders
(N = 47)
Poor responders
(N = 55)
p
Sex, N (%)
 Male69 (67.6)28 (59.6)41 (74.5)0.11
 Female33 (32.4)19 (40.4)14 (25.5) 
Age (years), N (%)
  < 6580 (78.4)35 (74.5)45 (81.8)0.37
  ≥ 6522 (21.6)12 (25.5)10 (18.2) 
AV distance (cm), N (%)
  < 562 (60.8)32 (68.1)30 (54.5)0.16
  ≥ 540 (39.2)15 (31.9)25 (45.5) 
CEA level (ng/mL), N (%)
  < 569 (67.6)30 (63.8)39 (70.9)0.45
  ≥ 533 (32.4)17 (36.2)16 (29.1) 
cT stage, N (%)
 T22 (2.0)1 (2.1)1 (1.8)0.17
 T377 (75.5)38 (80.9)39 (70.9) 
 T423 (22.5)8 (17.0)15 (27.3) 
cN stage, N (%)
 Negative52 (51.0)26 (55.3)26 (47.3)0.42
 Positive50 (49.0)21 (44.7)29 (52.7) 
Clinical LPLN metastasis, N (%)
 Negative78 (76.5)37 (78.7)41 (74.5)0.62
 Positive24 (23.5)10 (21.3)14 (25.5) 
Clinical CRM, N (%)
 Negative73 (71.6)34 (72.3)39 (70.9)0.87
 Positive29 (28.4)13 (27.7)16 (29.1) 
mrEMVI, N (%)
 Negative78 (76.5)38 (80.9)40 (72.7)0.34
 Positive24 (23.5)9 (19.1)15 (27.3) 
ymrEMVI, N (%)
 Negative80 (78.4)39 (83.0)41 (74.5)0.30
 Positive22 (21.6)8 (17.0)14 (25.5) 
  1. AV anal verge, CEA carcinoembryonic antigen, LPLN lateral pelvic lymph node, CRM circumferential resection margin, mrEMVI extramural venous invasion based on magnetic resonance imaging before neoadjuvant chemotherapy, ymrEMVI extramural venous invasion based on magnetic resonance imaging after neoadjuvant chemotherapy